PubMed:33048372 / 885-1188 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T10","span":{"begin":209,"end":220},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0007263"}],"text":"Compared to the referent group, recipients treated with other immunosuppression+HCQ had a 2-fold increased risk of abnormal ECG or QT prolongation (18.9% vs. 10.7%; aHR,1.12 1.963.42 , p=0.02) and ventricular arrhythmias (15.2% vs. 11.4%; aHR,1.00 1.813.29 , p=0.05) in the \u003e1-to-3 years posttransplant."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":88,"end":91},"obj":"http://purl.obolibrary.org/obo/CLO_0001562"},{"id":"T8","span":{"begin":88,"end":91},"obj":"http://purl.obolibrary.org/obo/CLO_0001563"}],"text":"Compared to the referent group, recipients treated with other immunosuppression+HCQ had a 2-fold increased risk of abnormal ECG or QT prolongation (18.9% vs. 10.7%; aHR,1.12 1.963.42 , p=0.02) and ventricular arrhythmias (15.2% vs. 11.4%; aHR,1.00 1.813.29 , p=0.05) in the \u003e1-to-3 years posttransplant."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T21","span":{"begin":25,"end":30},"obj":"Chemical"},{"id":"T22","span":{"begin":124,"end":127},"obj":"Chemical"}],"attributes":[{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_70255"}],"text":"Compared to the referent group, recipients treated with other immunosuppression+HCQ had a 2-fold increased risk of abnormal ECG or QT prolongation (18.9% vs. 10.7%; aHR,1.12 1.963.42 , p=0.02) and ventricular arrhythmias (15.2% vs. 11.4%; aHR,1.00 1.813.29 , p=0.05) in the \u003e1-to-3 years posttransplant."}

{"project":"LitCovid-PubTator","denotations":[{"id":"58","span":{"begin":80,"end":83},"obj":"Chemical"},{"id":"59","span":{"begin":131,"end":146},"obj":"Disease"},{"id":"60","span":{"begin":197,"end":220},"obj":"Disease"}],"attributes":[{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:D006886"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"MESH:D008133"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"MESH:D001145"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Compared to the referent group, recipients treated with other immunosuppression+HCQ had a 2-fold increased risk of abnormal ECG or QT prolongation (18.9% vs. 10.7%; aHR,1.12 1.963.42 , p=0.02) and ventricular arrhythmias (15.2% vs. 11.4%; aHR,1.00 1.813.29 , p=0.05) in the \u003e1-to-3 years posttransplant."}

{"project":"LitCovid-sentences","denotations":[{"id":"T9","span":{"begin":0,"end":303},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Compared to the referent group, recipients treated with other immunosuppression+HCQ had a 2-fold increased risk of abnormal ECG or QT prolongation (18.9% vs. 10.7%; aHR,1.12 1.963.42 , p=0.02) and ventricular arrhythmias (15.2% vs. 11.4%; aHR,1.00 1.813.29 , p=0.05) in the \u003e1-to-3 years posttransplant."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":115,"end":127},"obj":"Phenotype"},{"id":"T7","span":{"begin":197,"end":220},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0003115"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0004308"}],"text":"Compared to the referent group, recipients treated with other immunosuppression+HCQ had a 2-fold increased risk of abnormal ECG or QT prolongation (18.9% vs. 10.7%; aHR,1.12 1.963.42 , p=0.02) and ventricular arrhythmias (15.2% vs. 11.4%; aHR,1.00 1.813.29 , p=0.05) in the \u003e1-to-3 years posttransplant."}

{"project":"hydroxychloroquine","denotations":[{"id":"T6","span":{"begin":115,"end":127},"obj":"Phenotype"},{"id":"T7","span":{"begin":197,"end":220},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0003115"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0004308"}],"text":"Compared to the referent group, recipients treated with other immunosuppression+HCQ had a 2-fold increased risk of abnormal ECG or QT prolongation (18.9% vs. 10.7%; aHR,1.12 1.963.42 , p=0.02) and ventricular arrhythmias (15.2% vs. 11.4%; aHR,1.00 1.813.29 , p=0.05) in the \u003e1-to-3 years posttransplant."}